The certification, granted by BSI UK on July 7 under Regulation (EU) 2017/745, validates the safety and clinical performance of APHRANEL, a calcium hydroxyapatite-based technology. While regulatory approval clears the path for commercial distribution, MOYOM executives frame the milestone as a baseline rather than a final objective. The company is pivoting toward a long-term strategy focused on clinical credibility and physician education.

To bridge the gap between laboratory development and clinical application, MOYOM has engaged Dr. Patrick Trévidic and his organization, Expert2Expert. Dr. Trévidic, an aesthetic surgeon with over 35 years of experience, will oversee a series of independent scientific initiatives. These include cadaver studies, anatomy-based training programs, and the generation of new clinical data. According to Patrice Delobel, European Medical and Marketing Director at MOYOM, the collaboration is designed to build a robust scientific platform that practitioners can rely on for sustainable practice. The partnership maintains the scientific independence of the Expert2Expert team while utilizing their expertise to integrate APHRANEL into established aesthetic medicine frameworks across Europe.